Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
85690-5-PBS targets CYP17A1 in WB, IHC, Indirect ELISA applications and shows reactivity with human, mouse, rat samples.
| Tested Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen | CYP17A1 fusion protein Ag5899 相同性解析による交差性が予測される生物種 |
| Full Name | cytochrome P450, family 17, subfamily A, polypeptide 1 |
| Calculated molecular weight | 57 kDa |
| Observed molecular weight | 50-57 kDa |
| GenBank accession number | BC062997 |
| Gene Symbol | CYP17A1 |
| Gene ID (NCBI) | 1586 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P05093 |
| Storage Buffer | PBS only{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
The human cytochrome P450c17 enzyme is encoded by the CYP17A1 gene. It is the qualitative regulator of steroidogenesis in the human adrenals.In its absence, aldosterone is produced in the human adrenal zona glomerulosa .The CYP17A1 gene is expressed in the adrenal cortex and the gonads but not in the placenta (PMID;19403566). Although CYP17A1 has been shown to be a 50-kDa protein, the presence of a lower molecular mass(30 kDa) immunoreactive form in rat Leydig cells was previously shown and it is either a degradation product or a truncated form of the 50 kDa enzyme(PMID:15761033). Defects in CYP17A1 are the cause of adrenal hyperplasia type 5 (AH5) and CYP17A1 is an important target for inhibition in the treatment of prostate cancer (PMID 27505042, PMID 27505042).